By March 1, 2026 (revision date): Billing team must implement prior authorization requirements for all viscosupplement claims under Humana Medicaid-Indiana. (1) Update billing system to flag all claims for Durolane, Euflexxa, Gel-One, Gelsyn-3, GenVisc 850, Hyalgan, Hymovis, Hymovis-ONE, Monovisc, Orthovisc, Supartz FX, SynoJoynt, Synvisc, Synvisc-One, Triluron, TriVisc, and Visco-3 as requiring prior authorization. (2) Ensure prior auth requests include documented evidence of symptomatic knee osteoarthritis limited to the knee joint. (3) For patients requesting Gel-One, GenVisc 850, Hyalgan, Hymovis, Hymovis-ONE, Monovisc, Orthovisc, SynoJoynt, Synvisc, Synvisc-One, Triluron, TriVisc, or Visco-3, verify documentation of previous treatment failure, contraindication, or intolerance with at least TWO of the following: Durolane, Euflexxa, Gelsyn-3, or Supartz FX before submission. (4) For re-treatment requests, confirm at least 6 months have elapsed since the last treatment cycle and include this verification in the prior auth request. (5) Add patient allergy screening questions to encounter forms to identify known allergies to poultry/eggs/feathers (avian-derived products marked with *) and bacterial proteins (bacterial-derived products marked with ∞). (6) Train providers and front-desk staff on documentation requirements. Failure to obtain prior authorization or submit incomplete documentation will result in claim denials.